Affordable Access

Publisher Website

The efficacy of an anti-CD4 monoclonal antibody for HIV-1 treatment

Authors
Journal
Antiviral Research
0166-3542
Publisher
Elsevier
Volume
92
Issue
3
Identifiers
DOI: 10.1016/j.antiviral.2011.09.010
Keywords
  • Hiv-1
  • Monoclonal Antibody
  • Drug Resistance
  • Ibalizumab
Disciplines
  • Biology
  • Medicine

Abstract

Abstract The availability of 24 antiretroviral (ARV) drugs within six distinct drug classes has transformed HIV-1 infection (AIDS) into a treatable chronic disease. However, the ability of HIV-1 to develop resistance to multiple classes continues to present challenges to the treatment of many ARV treatment-experienced patients. In this case report, we describe the response to ibalizumab, an investigational CD4-binding monoclonal antibody (mAb), in a patient with advanced immunodeficiency and high-level five-class antiretroviral resistance. After starting an ibalizumab-based salvage regimen, the patient had an approximately 4.0 log10 reduction in viral load. An inadvertently missed infusion at week 32 led to the rapid loss of virologic response and decreased susceptibility to the remainder of the patient’s salvage therapy regimen. Following the reinstitution of ibalizumab, phenotypic and genotypic resistance to ibalizumab was detected. Nonetheless, plasma HIV-1 RNA levels stabilized at ∼2.0 log10 copies/ml below pre-ibalizumab levels. Continued ARV drug development may yield additional clinical and public health benefits. This report illustrates the promise of mAbs for HIV-1 therapy in highly treatment-experienced patients. Therapeutic mAbs may also have a role in pre-exposure prophylaxis in high-risk uninfected populations and may facilitate directly observed therapy (DOT) if two or more synergistic long acting agents become available.

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments

More articles like this

gp160 of HIV or anti-CD4 monoclonal antibody ligat...

on European Journal of Immunology February 1997

Neutralization of HIV-1 by F105, a human monoclona...

on Journal of acquired immune def... January 1993

Ibalizumab: an anti-CD4 monoclonal antibody for th...

on The Journal of antimicrobial c... September 2010

Depleting anti-CD4 monoclonal antibody (GK1.5) tre...

on Transplantation Journal Apr 27, 2008
More articles like this..